Sublingual misoprostol versus intramuscular oxytocin for prevention of post-partum haemorrhage in Uganda: a randomised, controlled, non-inferiority trial

Citation metadata

From: The Lancet(Vol. 384)
Publisher: Elsevier B.V.
Document Type: Article
Length: 141 words

Document controls

Main content

Abstract :

To link to full-text access for this article, visit this link: Byline: Esther C Atukunda, Mark J Siedner, Celestino Obua, Godfrey R Mugyenyi, Marc Twagirumukiza, Amon G Agaba Abstract: Postpartum haemorrhage is a leading cause of maternal death in sub-Saharan Africa. Although WHO recommends use of oxytocin for prevention of postpartum haemorrhage, misoprostol is increasingly used owing to advantages in shelf life, ease of use, storage, and potential for sublingual administration. We assessed the comparative efficacy of oxytocin and sublingual misoprostol for prevention of postpartum haemorrhage during labour. Author Affiliation: (a) Mbarara University of Science and Technology, Kampala, Uganda (b) Department of Medicine, Massachusetts General Hospital, Boston, MA, USA (c) Department of Pharmacology and Therapeutics, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda (d) Department of Pharmacology, Faculty of Medicine and Health Sciences, Ghent University, Belgium

Source Citation

Source Citation   

Gale Document Number: GALE|A395427612